Atlas Trials

Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)

Clinical trial NCT03990961 · TERMINATED

Trial details

NCT number
NCT03990961
Sponsor
University of Chicago
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Diffuse Large B Cell LymphomaLymphoma
Start date
2019-09-04
Primary completion
2024-04-01
Enrollment
5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.